Abstract:Bladder cancer (BC) is one of the most common malignancies in the United States, with over 80,000 new cases and 16,000 deaths each year. Urothelial carcinoma (UC) is the most common histology and accounts for 90% of cases. BC management is complicated by recurrence rates of over 50% in both muscle-invasive and non-muscle-invasive bladder cancer. As such, the American Urological Association (AUA) recommends that patients undergo close surveillance during and after treatment. This surveillance is in the form of cystoscopy or imaging tests, which can be invasive and costly tests. Considering this, there have been recent pushes to find complements to bladder cancer surveillance. Cell-free DNA (CfDNA), or DNA released from dying cells, and circulating tumor DNA (ctDNA), or mutated DNA released from tumor cells, can be analyzed to detect and characterize the molecular characteristics of tumors. Research has shown promising results for ctDNA use in the BC care realm. A PubMed literature review was performed finding studies discussing cfDNA and ctDNA in BC detection, prognostication, and monitoring for recurrence. Keywords used included bladder cancer, cell-free DNA, circulating tumor DNA, urothelial carcinoma, and liquid biopsy. Studies show that ctDNA can serve as prognostic indicators of both early- and late-stage BC, aid in risk stratification prior to major surgery, assist in detection of disease progression and metastatic relapse, and can assess patients who may respond to immunotherapy. The benefit of ctDNA is not confined to BC, as studies have also suggested its promise as a biomarker for neoadjuvant chemotherapy in upper-tract UC. However, there are some limitations to ctDNA that require improvements in ctDNA-specific detection methods and BC-specific mutations before widespread utilization can be achieved. Further prospective, randomized trials are needed to elucidate the true potential ctDNA has in advancements in BC care.

Research advances of urinary cell-free DNA in the detection and therapy of bladder cancer

Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

Superior Molecular Pathology of Urothelial Bladder Cancer Using Urinary Cell-Free DNA.

A Novel Cell-Free Single-Molecule Unique Primer Extension Resequencing (Cf-Super) Technology for Bladder Cancer Non-Invasive Detection in Urine

Applying fragmentomics profiles of urinary cell-free DNA for bladder cancer detection.

Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma

The potential use of urine cell free DNA as a marker for cancer

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

Advances in bladder cancer biology and therapy

Advances in Diagnosis and Therapy for Bladder Cancer

Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma

UroVysionTM Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives

The progress of urine DNA methylation detection in non-invasive diagnosis of bladder cancer

Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.

Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

Advancements in bladder cancer detection: a comprehensive review on liquid biopsy and cell-free DNA analysis

Urine biopsy technologies: Cancer and beyond

ChIP-seq of Urinary Cell-Free Chromatin Infers Tissue Origin and Detects Tumor-Derived Cell-Free DNA in Bladder Cancer

Single-cell sequencing and its applications in bladder cancer